Trial reportFrontiers in immunology2026
Long-term immune response to mRNA anti-SARS-CoV-2 vaccination in patients with cancer.
Trial report in Frontiers in immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
25 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Patients with cancer are at increased risk of morbidity and mortality from COVID-19 but were underrepresented in pivotal vaccine trials. Data on the magnitude and determinants of immune responses to mRNA SARS-CoV-2 vaccination in this population remain limited. Methods: I-SPARC is a prospective, phase IV clinical trial evaluating humoral and cellular immune responses to mRNA SARS-CoV-2 vaccination in 115 patients with cancer, including those receiving systemic therapy and those in remission. Anti-Spike antibody titers were measured longitudinally, and immunophenotyping was performed to assess T and B cell subsets. Clinical outcomes, including SARS-CoV-2 infection, were recorded. Results: All patients developed detectable anti-Spike antibodies, although absolute titers varied by cancer type and treatment. Patients with hematologic malignancies and/or receiving chemotherapy had the lowest anti-Spike antibody levels. Booster doses significantly increased titers, particularly in patients in remission or receiving non-cytotoxic therapies. Prior SARS-CoV-2 infection and the number of vaccine doses were associated with better responses. Immunophenotyping confirmed vaccine-induced expansion of memory T and B lymphocyte subpopulations. SARS-CoV-2 infection occurred in 16% of our cohort, with infrequent severe cases. Discussion: mRNA SARS-CoV-2 vaccines elicit robust humoral and cellular immune responses in patients with cancer, despite variability according to disease type and treatment. These findings support the use of booster strategies and provide a rationale for tailored vaccination approaches in immunocompromised populations.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.